218457-67-1
218457-67-1
Chemical Structure
Limantrafin
Synonym(s): CB-103
- CAS No.: 218457-67-1
- Formula:C15H18N2O
- Molecular Weight:242.32
IUPAC Name: 6-(4-(tert-butyl)phenoxy)pyridin-3-amine
InChIKey: WHIWGRCYMQLLAO-UHFFFAOYSA-N
SMILES: NC1=CC=C(OC2=CC=C(C(C)(C)C)C=C2)N=C1
Biological Activity: Limantrafin (CB-103) is a first-in-class, orally active protein-protein interaction (PPI) inhibitor of the NOTCH transcriptional activation complex. Limantrafin has anti-tumor activity[1][2][3][4].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Limantrafin | 99.97% | Limantrafin (CB-103) is a first-in-class, orally active protein-protein interaction (PPI) inhibitor of the NOTCH transcriptional activation complex. Limantrafin has anti-tumor activity. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Freddy Radtke, et al. Inhibitors of notch signalling pathway and use thereof in treatment of cancers. US9296682B2.
- [2]. R.Lehal, et al. Development of a novel first-in-class oral inhibitor of the NOTCH pathway.
- [3]. Rajwinder Lehal, et al. Non clinical pharmacology, pharmacokinetics and safety profiling of CB-103: A novel first-in-class small molecule inhibitor of the NOTCH pathway.
- [4]. Jose Manuel Perez Garcia, et al. First-in-human phase 1-2A study of CB-103, an oral Protein-Protein Interaction Inhibitor targeting pan-NOTCH signalling in advanced solid tumors and blood malignancies.
